BR0306309A - Derivados de 1,3,8-triazaespiro[4.5]decan-4-ona substituìda com hidroxialquila úteis para o tratamento de distúrbios mediados pelo receptor orl-1 - Google Patents

Derivados de 1,3,8-triazaespiro[4.5]decan-4-ona substituìda com hidroxialquila úteis para o tratamento de distúrbios mediados pelo receptor orl-1

Info

Publication number
BR0306309A
BR0306309A BR0306309-7A BR0306309A BR0306309A BR 0306309 A BR0306309 A BR 0306309A BR 0306309 A BR0306309 A BR 0306309A BR 0306309 A BR0306309 A BR 0306309A
Authority
BR
Brazil
Prior art keywords
disorders
treatment
decan
useful
triazaospiro
Prior art date
Application number
BR0306309-7A
Other languages
English (en)
Inventor
Kathleen Battista
Gilles Bignan
Peter J Connolly
Allen B Reitz
Tina Morgan Ross
Malcolm Scott
Steven A Middleton
Michael Orsini
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=31978719&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0306309(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of BR0306309A publication Critical patent/BR0306309A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Addiction (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

"DERIVADOS DE 1,3,8-TRIAZAESPIRO[4.5]DECAN-4-ONA SUBSTITUìDA COM HIDROXIALQUILA úTEIS PARA O TRATAMENTO DE DISTúRBIOS MEDIADOS PELO RECEPTOR ORL-1". A presente invenção refere-se a novos derivados de 1,3,8-triazaespiro[4.5]decan-4-ona substituída com hidroxialquila da fórmula geral onde todas as variáveis são como aqui definidas, úteis no tratamento de distúrbios e condições mediadas pelo receptor ORL-1 acoplado à proteína G. Mais particularmente, os compostos da presente invenção são úteis no tratamento de distúrbios e condições tais como ansiedade, depressão, pânico, demência, obsessão, distúrbio bipolar, dependência química, dor neuropática, dor aguda, dor crónica, enxaqueca, asma, tosse, psicose, esquizofrenia, epilepsia, hipertensão, obesidade, distúrbios de alimentação, ânsias, diabetes, arritmia cardíaca, síndrome do intestino irritável, doença de Crohn, incontinência urinária, distúrbios adrenais, distúrbio por deficiência de atenção (ADD), distúrbio por hiperatividade por deficiência de atenção (ADHD), mal de Alzheimer, para cognição ou memória desenvolvida e estabilização do humor.
BR0306309-7A 2002-09-09 2003-09-05 Derivados de 1,3,8-triazaespiro[4.5]decan-4-ona substituìda com hidroxialquila úteis para o tratamento de distúrbios mediados pelo receptor orl-1 BR0306309A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40913402P 2002-09-09 2002-09-09
PCT/US2003/027956 WO2004022558A2 (en) 2002-09-09 2003-09-05 Hydroxy alkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of orl-1 receptor mediated disorders

Publications (1)

Publication Number Publication Date
BR0306309A true BR0306309A (pt) 2004-10-19

Family

ID=31978719

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0306309-7A BR0306309A (pt) 2002-09-09 2003-09-05 Derivados de 1,3,8-triazaespiro[4.5]decan-4-ona substituìda com hidroxialquila úteis para o tratamento de distúrbios mediados pelo receptor orl-1

Country Status (19)

Country Link
US (3) US7081463B2 (pt)
EP (1) EP1601674B1 (pt)
JP (1) JP4712384B2 (pt)
KR (1) KR20050043935A (pt)
CN (1) CN100402529C (pt)
AR (1) AR041205A1 (pt)
AU (1) AU2003268512A1 (pt)
BR (1) BR0306309A (pt)
CA (1) CA2498275C (pt)
CL (1) CL2003001814A1 (pt)
EA (1) EA009369B1 (pt)
MX (1) MXPA05002622A (pt)
NO (1) NO20051743L (pt)
NZ (1) NZ538307A (pt)
PL (1) PL377047A1 (pt)
RS (1) RS20050208A (pt)
TW (1) TWI296627B (pt)
WO (1) WO2004022558A2 (pt)
ZA (1) ZA200502836B (pt)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003268512A1 (en) * 2002-09-09 2004-03-29 Janssen Pharmaceutica N.V. Hydroxy alkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders
NZ544282A (en) * 2003-05-23 2009-07-31 Zealand Pharma As Triaza-spiro compounds as nociceptin analogues and uses thereof
AR046756A1 (es) * 2003-12-12 2005-12-21 Solvay Pharm Gmbh Derivados de hidronopol como agonistas de receptores orl-1 humanos.
US20060178390A1 (en) * 2004-08-02 2006-08-10 Alfonzo Jordan 1,3,8-Triazaspiro[4,5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders
CA2623715A1 (en) 2005-09-28 2007-04-12 F. Hoffmann-La Roche Ag Indol-3-yl-carbonyl-azaspiro derivatives as vasopressin receptor antagonists
TW200819457A (en) * 2006-08-30 2008-05-01 Actelion Pharmaceuticals Ltd Spiro antibiotic derivatives
WO2008067177A2 (en) * 2006-11-28 2008-06-05 Janssen Pharmaceutica, N.V. Methods for the treatment of alcohol abuse, addiction and dependency
CN101622254B (zh) * 2006-11-28 2013-05-29 詹森药业有限公司 3-(3-氨基-2-(r)-羟基-丙基)-1-(4-氟-苯基)-8-(8-甲基-萘-1-基甲基)-1,3,8-三氮杂-螺[4.5]癸烷-4-酮的盐
JP5490677B2 (ja) * 2007-04-09 2014-05-14 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 不安及び鬱病の処置のためのｏｒｌ−１受容体リガンドとしての１，３，８−三置換−１，３，８−トリアザ−スピロ［４．５］デカン−４−オン誘導体
US20100076003A1 (en) * 2008-09-19 2010-03-25 Kathleen Battista 5-oxazolidin-2-one substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful as orl-1 receptor modulators
UA107943C2 (en) * 2009-11-16 2015-03-10 Lilly Co Eli Compounds of spiropiperidines as antagonists of the orl-1 receptors
CA2894126A1 (en) 2012-12-21 2014-06-26 Epizyme, Inc. Prmt5 inhibitors and uses thereof
CA2894157A1 (en) 2012-12-21 2014-06-26 Epizyme, Inc. Prmt5 inhibitors and uses thereof
WO2014100716A1 (en) * 2012-12-21 2014-06-26 Epizyme, Inc. Prmt5 inhibitors and uses thereof
US9604930B2 (en) 2012-12-21 2017-03-28 Epizyme, Inc. Tetrahydro- and dihydro-isoquinoline PRMT5 inhibitors and uses thereof
US8940726B2 (en) 2012-12-21 2015-01-27 Epizyme, Inc. PRMT5 inhibitors and uses thereof
TW201607923A (zh) 2014-07-15 2016-03-01 歌林達有限公司 被取代之氮螺環（４．５）癸烷衍生物
AU2015301196A1 (en) 2014-08-04 2017-01-12 Epizyme, Inc. PRMT5 inhibitors and uses thereof
JP6563017B2 (ja) 2014-08-28 2019-08-21 エースニューロン・ソシエテ・アノニム グリコシダーゼ阻害剤
US10112924B2 (en) 2015-12-02 2018-10-30 Astraea Therapeutics, Inc. Piperdinyl nociceptin receptor compounds
JP7011596B2 (ja) * 2015-12-02 2022-02-10 アストライア セラピューティクス， エルエルシー ピペリジニルノシセプチン受容体化合物
US11261183B2 (en) 2016-02-25 2022-03-01 Asceneuron Sa Sulfoximine glycosidase inhibitors
KR20180132060A (ko) 2016-02-25 2018-12-11 아셰뉴론 에스아 피페라진 유도체의 산 부가 염
EP3419971B1 (en) 2016-02-25 2022-04-20 Asceneuron SA Glycosidase inhibitors
MX2018010191A (es) 2016-02-25 2019-05-20 Asceneuron S A Inhibidores de glucosidasa.
EP3672959A1 (en) 2017-08-24 2020-07-01 Asceneuron SA Linear glycosidase inhibitors
RU2764243C2 (ru) 2017-09-22 2022-01-14 ДЖУБИЛАНТ ЭПИПЭД ЭлЭлСи Гетероциклические соединения в качестве ингибиторов PAD
PT3697785T (pt) 2017-10-18 2023-04-03 Jubilant Epipad LLC Compostos de imidazopiridina como inibidores de pad
KR20200085836A (ko) 2017-11-06 2020-07-15 주빌런트 프로델 엘엘씨 Pd1/pd-l1 활성화 억제제로서의 피리미딘 유도체
PT3704120T (pt) 2017-11-24 2024-07-03 Jubilant Episcribe Llc Compostos heterocíclicos como inibidores de prmt5
BR112020018610A2 (pt) 2018-03-13 2020-12-29 Jubilant Prodel LLC Compostos de fórmula i, fórmula ii, fórmula iii, fórmula iv, fórmula v, fórmula vi, ou seus polimorfos, estereoisômeros, tautômeros, profármacos, solvatos e sais farmaceuticamente aceitáveis dos mesmos e uso dos mesmos; processo de preparação; composição farmacêutica; e método para o tratamento e/ou prevenção de várias doenças, que incluem câncer e doenças infecciosas
WO2020039029A1 (en) * 2018-08-22 2020-02-27 Asceneuron S. A. Spiro compounds as glycosidase inhibitors
US12016852B2 (en) 2018-08-22 2024-06-25 Asceneuron Sa Pyrrolidine glycosidase inhibitors
WO2020039028A1 (en) 2018-08-22 2020-02-27 Asceneuron S. A. Tetrahydro-benzoazepine glycosidase inhibitors

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US677421A (en) * 1900-10-19 1901-07-02 Kate Hatch Mcrae Cake-beater.
US3155699A (en) * 1960-03-30 1964-11-03 Mobay Chemical Corp Purification of isocyanates by reduction of the hydrolyzable chlorine and acid content
US3161644A (en) * 1962-06-22 1964-12-15 Res Lab Dr C Janssen N V 1-benzyl-4-substituted piperidines
US3155670A (en) * 1962-06-22 1964-11-03 Res Lab Dr C Janssen N V 1-oxo-2, 4, 8, triaza-spiro (4, 5) decanes
US3238216A (en) 1963-06-20 1966-03-01 Res Lab Dr C Janssen N V Substituted 1, 3, 8-triaza-spiro (4, 5) decanes
US3839340A (en) * 1968-09-27 1974-10-01 Fmc Corp Substituted 1,3,8-triazaspiro{8 4.5{9 decanes
US3629267A (en) * 1968-10-28 1971-12-21 Smith Kline French Lab Benzoheterocyclicalkyl derivatives of 4-(2-keto -1-benzimidazolinyl)-piperidine 4-(2-keto - 1 - benzimidazolinyl) -1 2 3 6 tetrahydropyridine 1 - phenyl - 1 3 8-triazaspiro(4 5)decan - 4 - one and 2 4 9-triazaspiro(5 5)undecan-1 3 5-trione
US3859340A (en) * 1970-09-09 1975-01-07 Squibb & Sons Inc ' -methylfluorene-2-acetic acid
US4020072A (en) * 1976-05-04 1977-04-26 E. R. Squibb & Sons, Inc. 5-Aminomethyl-1H-pyrazolo[3,4-b]pyridines
JPS54109983A (en) * 1978-02-13 1979-08-29 Sumitomo Chem Co Ltd Novel spiroamine derivative and its preparation
US4329363A (en) * 1978-09-08 1982-05-11 Merck & Co., Inc. Substituted mercapto acid amides and their use
US4526896A (en) * 1978-12-26 1985-07-02 Riker Laboratories, Inc. Tetrazol-5-yl 2-nitro-3-phenylbenzofurans and antimicrobial use thereof
US4329353A (en) * 1980-10-22 1982-05-11 Janssen Pharmaceutica, N.V. 1-(4-Aryl-cyclohexyl)piperidine derivatives, method of use thereof and pharmaceutical compositions thereof
JPS57212180A (en) * 1981-06-19 1982-12-27 Yoshitomi Pharmaceut Ind Ltd Tetrahydrofuran(thiophene) compound
WO1988000190A1 (en) 1986-06-25 1988-01-14 Massachusetts Institute Of Technology Optically active derivatives of glycidol
IL96507A0 (en) 1989-12-08 1991-08-16 Merck & Co Inc Nitrogen-containing spirocycles and pharmaceutical compositions containing them
US5486362A (en) * 1991-05-07 1996-01-23 Dynagen, Inc. Controlled, sustained release delivery system for treating drug dependency
DE4135473A1 (de) 1991-10-28 1993-04-29 Bayer Ag Triazaspirodecanon-methylchromane
JPH08500326A (ja) 1991-12-27 1996-01-16 ベス イスラエル ホスピタル アソシエイション 免疫抑制剤としてのスピペロンまたはスピペロン誘導体の使用
FR2708606B1 (fr) 1993-07-30 1995-10-27 Sanofi Sa Dérivés du N-phénylalkylindol-2-one, leur préparation, les compositions pharmaceutiques en contenant.
EP0716661B1 (en) 1993-09-09 2000-04-05 Scios Inc. Pseudo- and non-peptide bradykinin receptor antagonists
US5739336A (en) 1995-06-23 1998-04-14 Syntex (U.S.A.) Inc. 1,3,8-triaza- and 3,8-diaza-1-oxaspiro 4,5! decane derivatives
US5821219A (en) 1995-08-11 1998-10-13 Oregon Health Sciences University Opioid antagonists and methods of their use
DE69728138T2 (de) 1996-03-29 2004-09-16 Pfizer Inc. 6-phenylpyridinderivate
CA2226058C (en) * 1997-01-30 2008-01-29 F. Hoffmann-La Roche Ag 8-substituted-1,3,8-triaza-spiro[4.5]decan-4-one derivatives
US6013652A (en) * 1997-12-04 2000-01-11 Merck & Co., Inc. Spiro-substituted azacycles as neurokinin antagonists
ATE212635T1 (de) * 1997-12-05 2002-02-15 1,3,8-triazaspiro(4,5)decan-4-on-derivate
SI0921125T1 (en) 1997-12-05 2002-04-30 F. Hoffmann-La Roche Ag 1,3,8-Triazaspiro(4,5)decan-4-on derivatives
WO1999059997A1 (en) * 1998-05-18 1999-11-25 Novo Nordisk A/S Novel 1,3,8-triazaspiro[4.5]decanones with high affinity for opioid receptor subtypes
US6277991B1 (en) * 1998-05-18 2001-08-21 Novo Nordisk A/S 1,3,8-triazaspiro[4.5]decanones with high affinity for opioid receptor subtypes
ATE204279T1 (de) 1998-06-12 2001-09-15 Hoffmann La Roche Diaza-spiro(3,5)nonan-derivate
EP1087770A4 (en) 1998-06-15 2001-11-14 Merck & Co Inc INHIBITORS OF PRENYL PROTEIN TRANSFERASE
ID29137A (id) * 1998-07-27 2001-08-02 Schering Corp Ligan-ligan afinitas tinggi untuk reseptor nosiseptin orl-1
US6262066B1 (en) * 1998-07-27 2001-07-17 Schering Corporation High affinity ligands for nociceptin receptor ORL-1
US6326379B1 (en) 1998-09-16 2001-12-04 Bristol-Myers Squibb Co. Fused pyridine inhibitors of cGMP phosphodiesterase
ES2237047T3 (es) * 1998-10-23 2005-07-16 Pfizer Inc. Compuestos de 1,3,8-triazaespiro(4,5)decanona como agonistas del receptor orl1.
MXPA01005095A (es) 1998-11-20 2002-04-24 Smithkline Beecham Spa Derivados de quinolin-4-carboxamida como antagonistas de receptor de neurocinina-3 y neurocinina-2.
JP2000169476A (ja) 1998-12-09 2000-06-20 Banyu Pharmaceut Co Ltd ４−オキソイミダゾリジン−５−スピロ−含窒素複素環式化合物
AU1382901A (en) 1999-11-17 2001-05-30 Novo Nordisk A/S Novel triazaspirodecanones with high affinity for opioid receptor subtypes
DE19956598A1 (de) 1999-11-25 2001-06-13 Bosch Gmbh Robert Ventil zum Steuern von Flüssigkeiten
JP3989247B2 (ja) * 1999-12-06 2007-10-10 ユーロ−セルティーク エス．エイ． ノシセプチン受容体親和性を有するトリアゾスピロ化合物
JP2005231995A (ja) 1999-12-22 2005-09-02 Meiji Seika Kaisha Ltd オピオイドδ受容体アゴニスト／アンタゴニストとして有用なスピロ化合物
GB0003224D0 (en) 2000-02-11 2000-04-05 Glaxo Group Ltd Chemical compounds
US6482829B2 (en) 2000-06-08 2002-11-19 Hoffmann-La Roche Inc. Substituted heterocyclic siprodecane compound active as an antagonist of neurokinin 1 receptor
WO2001096337A1 (fr) 2000-06-14 2001-12-20 Banyu Pharmaceutical Co.,Ltd Composes heterocycliques 4-oxoimidazolidine-2-spiro-azotes
EP1392687B1 (en) * 2001-04-10 2017-02-01 Janssen Pharmaceuticals, Inc. 1,3,8-triazaspiro[4,5]decan-4-one derivatives useful for the treatment of orl-1 receptor mediated disorders
RU2299883C2 (ru) 2001-04-18 2007-05-27 Эро-Селтик, С.А. Соединения спиропиразола, содержащая их фармацевтическая композиция, способ модуляции опиоидного рецептора и способ лечения с применением таких соединений
US20030078278A1 (en) * 2001-06-26 2003-04-24 Pfizer Inc. Spiropiperidine compounds as ligands for ORL-1 receptor
US7192964B2 (en) * 2001-07-23 2007-03-20 Banyu Pharmaceutical Co., Ltd. 4-oxoimidazolidine-2-spiropiperidine derivatives
US20040014955A1 (en) * 2001-12-17 2004-01-22 Carlos Zamudio Identification of essential genes of cryptococcus neoformans and methods of use
EP1470126A1 (en) * 2002-01-28 2004-10-27 Pfizer Inc. N-substituted spiropiperidine compounds as ligands for orl-1 receptor
US20060058553A1 (en) 2002-02-07 2006-03-16 Axys Pharmaceuticals, Inc. Novel bicyclic hydroxamates as inhibitors of histone deacetylase
AU2003268512A1 (en) * 2002-09-09 2004-03-29 Janssen Pharmaceutica N.V. Hydroxy alkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders
WO2005016913A1 (en) 2003-08-19 2005-02-24 Pfizer Japan, Inc. Tetrahydroisoquinoline or isochroman compounds as orl-1 receptor ligands for the treatment of pain and cns disorders
EP1716148A2 (en) 2003-12-23 2006-11-02 Arena Pharmaceuticals, Inc. Novel spiroindoline or spiroisoquinoline compounds, methods of use and compositions thereof
NZ553202A (en) 2004-08-19 2010-12-24 Vertex Pharma Modulators of muscarinic receptors
JP2008513476A (ja) 2004-09-17 2008-05-01 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド ｃ−Ｋｉｔ癌原遺伝子阻害剤としての（スピロシクリルアミド）アミノチオフェン化合物
US7655670B2 (en) * 2005-06-02 2010-02-02 Janssen Pharmaceutica N.V. 3-spirocyclic indolyl derivatives useful as ORL-1 receptor modulators
WO2008067177A2 (en) 2006-11-28 2008-06-05 Janssen Pharmaceutica, N.V. Methods for the treatment of alcohol abuse, addiction and dependency
JP5490677B2 (ja) 2007-04-09 2014-05-14 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 不安及び鬱病の処置のためのｏｒｌ−１受容体リガンドとしての１，３，８−三置換−１，３，８−トリアザ−スピロ［４．５］デカン−４−オン誘導体
US20100076003A1 (en) 2008-09-19 2010-03-25 Kathleen Battista 5-oxazolidin-2-one substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful as orl-1 receptor modulators

Also Published As

Publication number Publication date
PL377047A1 (pl) 2006-01-23
WO2004022558A3 (en) 2004-05-21
US8778956B2 (en) 2014-07-15
TWI296627B (en) 2008-05-11
US20040142955A1 (en) 2004-07-22
ZA200502836B (en) 2006-06-28
CN100402529C (zh) 2008-07-16
KR20050043935A (ko) 2005-05-11
US20090124614A1 (en) 2009-05-14
RS20050208A (en) 2007-08-03
NZ538307A (en) 2008-04-30
CL2003001814A1 (es) 2005-02-11
US7081463B2 (en) 2006-07-25
AR041205A1 (es) 2005-05-11
EA009369B1 (ru) 2007-12-28
CN1694883A (zh) 2005-11-09
JP2006500393A (ja) 2006-01-05
US7582649B2 (en) 2009-09-01
CA2498275A1 (en) 2004-03-18
JP4712384B2 (ja) 2011-06-29
TW200418857A (en) 2004-10-01
AU2003268512A1 (en) 2004-03-29
WO2004022558A2 (en) 2004-03-18
NO20051743L (no) 2005-05-18
EA200500331A1 (ru) 2005-08-25
EP1601674A2 (en) 2005-12-07
US20060030577A1 (en) 2006-02-09
CA2498275C (en) 2011-07-12
EP1601674B1 (en) 2012-08-08
MXPA05002622A (es) 2005-09-08

Similar Documents

Publication Publication Date Title
BR0306309A (pt) Derivados de 1,3,8-triazaespiro[4.5]decan-4-ona substituìda com hidroxialquila úteis para o tratamento de distúrbios mediados pelo receptor orl-1
Kumar et al. Synthesis and anti-bacterial activity of some novel 2-(6-fluorochroman-2-yl)-1-alkyl/acyl/aroyl-1H-benzimidazoles
Yang et al. A cell-based target engagement assay for the identification of cereblon E3 ubiquitin ligase ligands and their application in HDAC6 degraders
ATE203023T1 (de) Tropanderivate, deren herstellung und verwendung
GIANT Consortium Willer Cristen J 1 Speliotes Elizabeth K 2 3 Loos Ruth JF 4 5 Li Shengxu 4 5 Lindgren Cecilia M 6 Heid Iris M 7 Berndt Sonja I 8 Elliott Amanda L 9 10 Jackson Anne U 1 Lamina Claudia 7 Lettre Guillaume 9 11 Lim Noha 12 Lyon Helen N 3 11 McCarroll Steven A 9 10 Papadakis Konstantinos 13 Qi Lu 14 15 Randall Joshua C 6 Roccasecca Rosa Maria 16 Sanna Serena 17 Scheet Paul 18 Weedon Michael N 19 Wheeler Eleanor 16 Zhao Jing Hua 4 5 Jacobs Leonie C 20 Prokopenko Inga 6 21 Soranzo Nicole 16 22 Tanaka Toshiko 23 Timpson Nicholas J 24 Almgren Peter 25 Bennett Amanda 26 Bergman Richard N 27 Bingham Sheila A 28 29 Bonnycastle Lori L 30 Brown Morris 31 Burtt Noël P 9 Chines Peter 30 Coin Lachlan 32 Collins Francis S 30 Connell John M 33 Cooper Cyrus 34 Smith George Davey 24 Dennison Elaine M 34 Deodhar Parimal 30 Elliott Paul 32 Erdos Michael R 30 Estrada Karol 20 Evans David M 24 Gianniny Lauren 9 Gieger Christian 7 Gillson Christopher J 4 5 Guiducci Candace 9 Hackett Rachel 9 Hadley David 13 Hall Alistair S 35 Havulinna Aki S 36 Hebebrand Johannes 37 Hofman Albert 38 Isomaa Bo 39 Jacobs Kevin B 40 Johnson Toby 41 42 43 Jousilahti Pekka 36 Jovanovic Zorica 5 44 Khaw Kay-Tee 45 Kraft Peter 46 Kuokkanen Mikko 9 47 Kuusisto Johanna 48 Laitinen Jaana 49 Lakatta Edward G 50 Luan Jian'an 4 5 Luben Robert N 45 Mangino Massimo 51 McArdle Wendy L 52 Meitinger Thomas 53 54 Mulas Antonella 17 Munroe Patricia B 55 Narisu Narisu 30 Ness Andrew R 56 Northstone Kate 52 O'Rahilly Stephen 5 44 Purmann Carolin 5 44 Rees Matthew G 30 Ridderstråle Martin 57 Ring Susan M 52 Rivadeneira Fernando 20 38 Ruokonen Aimo 58 Sandhu Manjinder S 4 45 Saramies Jouko 59 Scott Laura J 1 Scuteri Angelo 60 Silander Kaisa 47 Sims Matthew A 4 5 Song Kijoung 12 Stephens Jonathan 61 Stevens Suzanne 51 Stringham Heather M 1 Tung YC Loraine 5 44 Valle Timo T 62 Van Duijn Cornelia M 38 Vimaleswaran Karani S 4 5 Vollenweider Peter 63 Waeber Gerard 63 Wallace Chris 55 Watanabe Richard M 64 Waterworth Dawn M 12 Watkins Nicholas 61 Witteman Jacqueline CM 38 Zeggini Eleftheria 6 Zhai Guangju 22 Zillikens M Carola 20 Altshuler David 9 10 Caulfield Mark J 55 Chanock Stephen J 8 Farooqi I Sadaf 5 44 Ferrucci Luigi 23 Guralnik Jack M 65 Hattersley Andrew T 66 Hu Frank B 14 15 Jarvelin Marjo-Riitta 32 Laakso Markku 48 Mooser Vincent 12 Ong Ken K 4 5 Ouwehand Willem H 16 61 Salomaa Veikko 36 Samani Nilesh J 51 Spector Timothy D 22 Tuomi Tiinamaija 67 68 Tuomilehto Jaakko 62 Uda Manuela 17 Uitterlinden André G 20 38 Wareham Nicholas J 4 5 Deloukas Panagiotis 16 Frayling Timothy M 19 Groop Leif C 25 69 Hayes Richard B 8 Hunter David J 9 14 15 46 Mohlke Karen L 70 Peltonen Leena 9 16 71 Schlessinger David 72 Strachan David P 13 Wichmann H-Erich 7 73 McCarthy Mark I mark. mccarthy@ drl. ox. ac. uk 6 21 74 fd Boehnke Michael boehnke@ umich. edu 1 fe Barroso Inês ib1@ sanger. ac. uk 16 ff Abecasis Gonçalo R goncalo@ umich. edu 18 fg Hirschhorn Joel N joelh@ broad. mit. edu 3 11 75 fh Six new loci associated with body mass index highlight a neuronal influence on body weight regulation
Molinari et al. Oligosaccharyltransferase-subunit mutations in nonsyndromic mental retardation
Calcaterra et al. Chemical, computational and functional insights into the chemical stability of the Hedgehog pathway inhibitor GANT61
BRPI0408910A (pt) composto, composição farmacêutica e métodos para a profilaxia ou o tratamento de doenças ou condições e para a produção de uma composição farmacêutica
ATE402935T1 (de) Kondensierte heterocyclische verbindungen und deren verwendung als antagonisten des metabotropen rezeptors zur behandlung von gastrointestinalen erkrankungen
BRPI0607456A2 (pt) derivados de oxindol como agonistas do receptor 5ht4
BRPI0411661A (pt) derivados de n-fenil-piperazina e métodos de profilaxia ou tratamento de doenças associadas com o receptor 5ht 2c
BR0314201A (pt) Compostos diazabicìclicos úteis no tratamento de doenças do cns e outros distúrbios
Kumar et al. Design, synthesis and pharmacological evaluation of some novel derivatives of 1-{[3-(furan-2-yl)-5-phenyl-4, 5-dihydro-1, 2-oxazol-4-yl] methyl}-4-methyl piperazine
Kolanos et al. Binding of isotryptamines and indenes at h5-HT6 serotonin receptors
Lee et al. Gender effect of catechol-O-methyltransferase Val158Met polymorphism on suicidal behavior
Pietrancosta et al. Novel cyclized Pifithrin-α p53 inactivators: synthesis and biological studies
Parnell et al. Evidence against stabilization of the transition state oxyanion by a pKa-perturbed RNA base in the peptidyl transferase center
Seley et al. Synthesis and anti-trypanosomal activity of various 8-Aza-7-deaza-5 ‘-noraristeromycin derivatives
ATE290857T1 (de) Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen
Li et al. Synthesis and biological evaluation of p38α kinase-targeting dialkynylimidazoles
EA201000847A1 (ru) Способ получения кондесационной смолы
ATE334680T1 (de) 4-aminopiperidin-derivate, verfahren zur herstellung und ihre verwendung als arzneimittel
CN108368062A (zh) Nk1受体拮抗剂
Martín-Martínez et al. Conformationally constrained CCK4 analogues incorporating IBTM and BTD β-turn mimetics
Haadsma-Svensson et al. C-9 and N-Substituted Analogs of cis-(3aR)-(-)-2, 3, 3a, 4, 5, 9b-Hexahydro-3-propyl-1H-benz [e] indole-9-carboxamide: 5-HT1A Receptor Agonists with Various Degrees of Metabolic Stability

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: NAO APRESENTADA A GUIA DE CUMPRIMENTO DE EXIGENCIA. REFERENTE A 8A ANUIDADE.